Linagliptin

Routes
Oral (PO)
Half-Life (t½)
PO: 12h
Formula
C25H28N8O2
Molecular Weight
472.54 g/mol
PubChem CID
10096344
Aliases
Tradjenta, Trajenta, BI-1356

Pharmacological Mechanism

Highly selective, tight-binding DPP-4 inhibitor — prevents inactivation of endogenous GLP-1 and GIP → enhanced glucose-dependent insulin release and suppressed glucagon. Unique among DPP-4 inhibitors in being eliminated primarily unchanged via bile/feces (<5% renal) with a non-linear PK driven by saturable DPP-4 target binding — effective t½ ~12 h despite terminal t½ of 100+ h due to target-mediated disposition.

Half-Life & Elimination Curve (PO: 12h)

100%50%25%12.5%0%0h0×t½12h1×t½24h2×t½36h3×t½48h4×t½60h5×t½0×t½ (0h): 100% remaining1×t½ (12h): 50% remaining2×t½ (24h): 25% remaining3×t½ (36h): 12.5% remaining4×t½ (48h): 6.3% remaining5×t½ (60h): 3.1% remaining
Plasma (PO)t½ Decay (12h)Effect Site (ke0)
  • 0×t½0h100%
  • 1×t½12h50%
  • 2×t½24h25%
  • 3×t½36h12.5%
  • 4×t½48h6.3%
  • 5×t½60h3.1%
Elimination t½12h (PO)
Rate Constant (ke)0.0578 h⁻¹
Time to Peak (Tmax)1.75h
97% Washout (5×t½)60h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References